OndÅ**e**MKubeÄ**e**k

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8189041/publications.pdf

Version: 2024-02-01

19 papers 308 citations

8 h-index 17 g-index

24 all docs

24 docs citations

times ranked

24

532 citing authors

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Prognostic value of blood cell count-derived ratios in BRAF-mutated metastatic melanoma. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2022, 166, 393-404. | 0.6 | 2 |
| 2 | Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors. In Vivo, 2021, 35, 2981-2990. | 1.3 | 1 |
| 3 | Clinicopathological Characteristics and Prognostic Factors in Ovarian Metastases from Right- and Left-Sided Colorectal Cancer. Current Oncology, 2021, 28, 2914-2927. | 2.2 | 1 |
| 4 | Combined Therapy of Locally Advanced Oesophageal and Gastro–Oesophageal Junction Adenocarcinomas: State of the Art and Aspects of Predictive Factors. Cancers, 2021, 13, 4591. | 3.7 | 0 |
| 5 | Risk Factors for Infections, Antibiotic Therapy, and Its Impact on Cancer Therapy Outcomes for Patients with Solid Tumors. Life, 2021, 11, 1387. | 2.4 | 6 |
| 6 | Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer. Cancer Chemotherapy and Pharmacology, 2020, 85, 353-365. | 2.3 | 4 |
| 7 | Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years. Pharmaceutics, 2020, 12, 940. | 4.5 | 3 |
| 8 | Distant Metastasis in Colorectal Cancer Patients—Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review. International Journal of Molecular Sciences, 2020, 21, 5255. | 4.1 | 38 |
| 9 | How to manage side effects of immunotherapy. Onkologie (Czech Republic), 2020, 14, 6-12. | 0.1 | O |
| 10 | Hepatic Injury Induced by a Single Dose of Nivolumab – a Case Report and Literature Review. Klinicka Onkologie, 2019, 32, 133-138. | 0.3 | 17 |
| 11 | Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report. Journal of Medical Case Reports, 2018, 12, 262. | 0.8 | 44 |
| 12 | The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review. Clinical and Experimental Metastasis, 2017, 34, 295-307. | 3.3 | 99 |
| 13 | Dermatomyositis with anti-TIF- $1\hat{l}^3$ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report. BMC Cancer, 2016, 16, 684. | 2.6 | 12 |
| 14 | Microsatellite instability in melanoma: a comprehensive review. Melanoma Research, 2016, 26, 545-550. | 1.2 | 26 |
| 15 | Microsatellite instability as a predictive factor for immunotherapy in malignant melanoma. Medical Hypotheses, 2016, 93, 74-76. | 1.5 | 14 |
| 16 | Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression. Cancer Chemotherapy and Pharmacology, 2016, 77, 429-437. | 2.3 | 6 |
| 17 | Extracorporeal apheresis system - A nanoparticle drugs' elimination method to enhance the benefit of cytostatic therapy in cancer patients. Journal of Applied Biomedicine, 2016, 14, 91-96. | 1.7 | 1 |
| 18 | Treatment possibilities of ipilimumab-induced thrombocytopeniacase study and literature review. Japanese Journal of Clinical Oncology, 2015, 45, 381-384. | 1.3 | 28 |

ARTICLE IF CITATIONS

Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the
Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients. Acta Medica (Hradec) Tj ETQq1 1 0.784.314 rgBT/Overlo